Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 403, 2000, Pages 62-66

  Crown, W H ^a   Judge, R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Depression; Outcomes; Pharmacoeconomics; SSRI; TCA

Indexed keywords

DESIPRAMINE; FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL PROTOCOL; CONFERENCE PAPER; DATA BASE; DEPRESSION; DRUG USE; ECONOMIC ASPECT; MEDICAID; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; FOLLOW-UP STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0033813232     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Economic analysis of health care technology: A report on principles
2. A reappraisal of economic evaluation of pharmaceuticals: Science or marketing?
3. Cost-effectiveness comparisons using real-world randomized trials - The case of new antidepressant drugs
4. SSRI and TCA antidepressant selection and health care costs: A multivariate analyses
5. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs. tricyclic antidepressants
6. Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom
7. Fluoxetine: A pharmacoeconomic evaluation of its use in depression
8. Noncompliance with antidepressants: Who's to blame?
9. Long-term outcomes of initial antidepressant choice in a 'real-world' randomized trial
10. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization
11. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization
12. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression
13. Antidepressant pharmacotherapy: Effect on women's resource utilization within a health maintenance organization
14. A comparison of the cost-effectiveness of sertraline vs. tricyclic antidepressants in primary care
15. Effect of antidepressant therapy on health care utilization and costs in primary care
16. Economic evaluation of paroxetine and imipramine in depressed outpatient
17. Acute medical costs of fluoxetine versus tricyclic antidepressants: A prospective multicentre study of antidepressant drug overdoses
18. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy
19. Antidepressant selection and use and healthcare expenditures: An empirical approach
20. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization
21. Cost implications of initial antidepressant selection in primary care
22. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program
23. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization
24. Costes del tratamiento con nuevos antidepresivos en la practica clinics
25. Antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
26. A pharmacoeconomic study of the management of major depression: Patients in a TennCare HMO
27. A cost-effective approach to the use of selective serotonin reuptake inhibitors in a Veterans Affairs Medical Center
28. An economic analysis of physicians' prescribing of selective serotonin reuptake inhibitors